More Education

Blog Commonsense State Rules Ease Access to Biosimilars

Health care in the United States has quietly turned a big corner. Just as the FDA approved its first interchangeable biosimilar, Oklahoma became the 50th and final state where pharmacists can substitute these lower-cost versions of biologic drugs.

Read More

Related Content

Paper What Patients Should Know About Biologics

Event Report AfPA’s 2024 National Policy & Advocacy Summit Report

Paper Nurturing the Potential of the Biosimilar Market

Stay Informed View the latest newsletter

To receive regular newsletters and periodic alerts from the BPC, enter your email address in the form below:

(function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';fnames[1]='FNAME';ftypes[1]='text';fnames[2]='LNAME';ftypes[2]='text';}(jQuery));var $mcj = jQuery.noConflict(true);